CBLI - Cleveland BioLabs, Inc.
| Previous Close | 1.81 |
| Open | 1.88 |
| Bid | 1.86 x 800 |
| Ask | 2.18 x 800 |
| Day's Range | 1.81 - 1.99 |
| 52 Week Range | 1.76 - 4.25 |
| Volume | 8,614 |
| Avg. Volume | 18,182 |
| Market Cap | 22.031M |
| Beta | -1.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.40 |
| Earnings Date | May 18, 2017 - May 19, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.00 |
- ACCESSWIRE•last month
Cleveland Biolabs Reports Second Quarter 2018 Financial Results And Development Progress
BUFFALO, NY / ACCESSWIRE / August 14, 2018 / Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the second quarter ended June 30, 2018. Cleveland BioLabs ...
- ACCESSWIRE•last month
Cleveland Biolabs Announces Formation and Financing of an Anti-Aging Joint Venture
BUFFALO, NY / ACCESSWIRE / August 14, 2018 / Cleveland BioLabs, Inc. (CBLI) today reported formation of a 50-50 joint venture, named Genome Protection, Inc. (GPI), between the company and Everon BioSciences, Inc. (Everon), a leader in understanding and targeting cellular mechanisms of aging and age-related diseases. GPI's goal is to develop and commercialize drugs for anti-aging applications capable of prolonging human health and life-span. CBLI and Everon contributed relevant IP, technologies and expertise to enable GPI to effectively execute an ambitious research and development program aimed at clinical testing of entolimod and development of new products for anti-aging and other indications associated with genome damage.
- ACCESSWIRE•last month
Cleveland BioLabs Announces Delay in Analysis of Biocomparability Data Required for Regulatory Submission
BUFFALO, NY / ACCESSWIRE / August 6, 2018 / Cleveland BioLabs, Inc. (CBLI) today reported that the company has received vendor notification of delays in analytical analyses of a formulation biocomparability study required for the Company's regulatory submissions. Because the review by the United States Food and Drug Administration (FDA) of the company's pre-Emergency Use Authorization application does not take place on strict timelines, entolimod's review status with the FDA is unaffected.
- American City Business Journals•3 months ago
Ikea’s departure from Cary leads to impairment charge for mall owner
In the wake of Ikea’s departure from Cary Towne Center, the mall’s owner is moving toward an impairment charge on its books, according to public filings from the company.
- ACCESSWIRE•3 months ago
Wired News – Alnylam Pharma Presented New Encouraging Results from Phase-1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type-1
LONDON, UK / ACCESSWIRE / June 12, 2018 / If you want access to our free research report on Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ALNY as the Company’s latest news hit the wire. On June 08, 2018, the Company presented updated positive results from its Phase-1/2 study assessing lumasiran for the treatment of Primary Hyperoxaluria Type-1 (PH1) at the OxalEurope, European Hyperoxaluria Consortium in Naples, Italy. Active-Investors.com is currently working on the research report for Cleveland BioLabs, Inc. (NASDAQ: CBLI), which also belongs to the Healthcare sector as the Company Alnylam Pharma.
- Simply Wall St.•4 months ago
Should You Be Concerned About Cleveland BioLabs Inc’s (NASDAQ:CBLI) Investors?
In this analysis, my focus will be on developing a perspective on Cleveland BioLabs Inc’s (NASDAQ:CBLI) latest ownership structure, a less discussed, but important factor. Ownership structure has been foundRead More...
- ACCESSWIRE•4 months ago
Cleveland Biolabs Reports First Quarter 2018 Financial Results and Development Progress
BUFFALO, NY / ACCESSWIRE / May 15, 2018 / Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the first quarter ended March 31, 2018. Cleveland BioLabs ...
- Simply Wall St.•5 months ago
Is Cleveland BioLabs Inc’s (NASDAQ:CBLI) CEO Being Overpaid?
Yakov Kogan took the helm as Cleveland BioLabs Inc’s (NASDAQ:CBLI) CEO and grew market cap to US$33.22M recently. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...
- ACCESSWIRE•6 months ago
Cleveland Biolabs Announces Progress on European Marketing Authorization Application
BUFFALO, NY / ACCESSWIRE / March 28, 2018 / Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported that the company has received Day 120 review questions from the European Medicines Agency (EMA) regarding ...
- ACCESSWIRE•6 months ago
Cleveland Biolabs Reports 2017 Financial Results and Development Progress
BUFFALO, NY / ACCESSWIRE / March 6, 2018 / Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the fourth quarter and year ended December 31, 2017. Cleveland ...
- Simply Wall St.•7 months ago
Should You Be Concerned About Cleveland BioLabs Inc’s (NASDAQ:CBLI) Investors?
Today, I will be analyzing Cleveland BioLabs Inc’s (NASDAQ:CBLI) recent ownership structure, an important but not-so-popular subject among individual investors. When it comes to ownership structure of a company, theRead More...
- Simply Wall St.•7 months ago
Have Investors Already Priced In Healthcare Growth For Cleveland BioLabs Inc (NASDAQ:CBLI)?
Cleveland BioLabs Inc (NASDAQ:CBLI), a US$39.37M small-cap, is a healthcare company operating in an industry, which has experienced tailwinds from issues such as higher demand driven by an aging populationRead More...
- Simply Wall St.•9 months ago
Is Cleveland BioLabs Inc’s (NASDAQ:CBLI) CEO Incentives Align With Yours?
Yakov Kogan took the reins as CEO of Cleveland BioLabs Inc’s (NASDAQ:CBLI) and grew market cap to $45.23M recently. Understanding how CEOs are incentivised to run and grow their companyRead More...
- Simply Wall St.•9 months ago
Is Cleveland BioLabs Inc (NASDAQ:CBLI) As Financially Strong As Its Balance Sheet Indicates?
Cleveland BioLabs Inc (NASDAQ:CBLI), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is CBLIRead More...
- ACCESSWIRE•10 months ago
Wired News – FDA Cleared IND Application of Capricor to Conduct Phase-2 Trial of CAP-1002 for Duchenne Muscular Dystrophy
Stock Monitor: Cleveland BioLabs Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 01, 2017 / Active-Investors issued a free report on Capricor Therapeutics, Inc. (NASDAQ: CAPR ), which is readily ...
- Capital Cube•10 months ago
ETFs with exposure to Cleveland BioLabs, Inc. : November 30, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Cleveland BioLabs, Inc. Here are 5 ETFs with the largest exposure to CBLI-US. Comparing the performance and risk of Cleveland BioLabs, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
- Capital Cube•10 months ago
Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
Categories: Yahoo FinanceGet free summary analysis Cleveland BioLabs, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Cleveland BioLabs, Inc. – Onconova Therapeutics Inc., OPKO Health, Inc., Novartis AG Sponsored ADR, Bristol-Myers Squibb Company, Cascadian Therapeutics Inc., Amgen Inc., Eli Lilly and Company and GlaxoSmithKline ... Read more (Read more...)
- Simply Wall St.•10 months ago
What Does Cleveland BioLabs Inc’s (CBLI) Ownership Structure Look Like?
Today, I will be analyzing Cleveland BioLabs Inc’s (NASDAQ:CBLI) recent ownership structure, an important but not-so-popular subject among individual investors. When it comes to ownership structure of a company, theRead More...
- Capital Cube•10 months ago
ETFs with exposure to Cleveland BioLabs, Inc. : November 15, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Cleveland BioLabs, Inc. Here are 5 ETFs with the largest exposure to CBLI-US. Comparing the performance and risk of Cleveland BioLabs, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
- Marketwired•10 months ago
Cleveland BioLabs Reports Third Quarter 2017 Financial Results and Development Progress
Cleveland BioLabs, Inc. today reported financial results and development progress for the third quarter ended September 30, 2017.
- Simply Wall St.•10 months ago
How Does Cleveland BioLabs Inc (CBLI) Compare To The Healthcare Sector?
Cleveland BioLabs Inc (NASDAQ:CBLI), a USD$30.57M small-cap, operates in the healthcare industry, which has experienced tailwinds from issues such as higher demand driven by an aging population and the increasingRead More...
- Capital Cube•last year
ETFs with exposure to Cleveland BioLabs, Inc. : September 19, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Cleveland BioLabs, Inc. Here are 5 ETFs with the largest exposure to CBLI-US. Comparing the performance and risk of Cleveland BioLabs, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
